Materials and methods for preparing protein-polymer conjugates

• US 9,040,664 B2
• Filed: 04/08/2004
• Issued: 05/26/2015
• Est. Priority Date: 04/11/2003
• Status: Expired due to Fees

• Current Assignee: Rezolute, Inc.
• Original Assignee: AntriaBio, Inc.
• Inventors: Hinds, Kenneth, Lewis, Danny, Schmidt, Paul, Campbell, Kathleen M.
• Primary Examiner(s): ROBINSON, HOPE A
• Application Number:
  US10/553,570
• Publication Number:
  US 20070083006A1
• Time in Patent Office: 4,065 Days
• Field of Search: None
• US Class Current: 530/350
• CPC Class Codes: A61K 38/28 Insulins
• CPC Class Codes: A61K 47/60 the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
• CPC Class Codes: A61K 9/5031 obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
• CPC Class Codes: A61P 1/18 for pancreatic disorders, e.g. pancreatic enzymes
• CPC Class Codes: A61P 3/10 for hyperglycaemia, e.g. antidiabetics
• CPC Class Codes: C07K 14/62 Insulins

Abstract

The invention is directed to a single-step method for rapidly and efficiently preparing protein-polymer conjugates, including an insulin-polymer conjugate. According to the method of the present invention, a protein and hydrophilic polymer are contacted in the presence of at least one organic solvent and at least one metal chelator, under conditions that promote the formation of a conjugate of the protein and polymer. Thus, the invention is directed to the site-specific modification of selected proteins, such as insulin, with poly(ethylene glycol) at residue PheB1. The invention also provides a pharmaceutical formulation for encapsulating the conjugate in a biodegradable polymer.

Claims

1. A method for preparing a site-specific insulin-PEG conjugate comprising:

(a) contacting insulin protein with PEG in an aqueous solution in the presence of at least one organic solvent selected from the group consisting of ethanol, methanol, DMSO, dioxane, DMF, and NMP and at least one metal chelator selected from the group consisting of metal ion chelators, EDTA, deferoxamine (DEF), diethylenetriamine pentaacetic acid (DTPA), and bis(aminoethyl)glycolether N,N,N′

,N′

-tetraacetic acid (EGTA), to form the site-specific insulin-PEG conjugate by a predominant reaction of the insulin protein at residue PheB1 without protecting the insulin protein at GlyA1 and LysB29 residues, and

(b) isolating the conjugate.

2. The method of claim 1, wherein the insulin protein comprises human insulin.

3. The method of claim 1, wherein the PEG comprises an amino-reactive PEG derivative selected from the group consisting of an aldehyde, a N-hydroxy succinimide, a PNP-carbonate, and a benzotrizole terminated hydrophilic polymer.

4. The method of claim 1, wherein the PEG and insulin protein are contacted at a molar ratio of about 10:

1-1;

1.

5. The method of claim 1, wherein the organic solvent is present at a concentration of about 0.1 to 10%.

6. The method of claim 1, wherein the insulin protein and the PEG are contacted at a pH of about 5.0-7.5.

7. The method of claim 1, wherein the metal chelator is present at a concentration of about 0.1-10 mM.

8. The method of claim 1, wherein the insulin protein and the PEG are contacted at a temperature of about 4-50°

C.

9. The method of claim 1, wherein the method further comprises the step of quenching formation of the conjugate prior to the isolating of the conjugate.

10. The method of claim 1, further comprising the step of:

(c) encapsulating the isolated conjugate in a biodegradable polymer.